Dogwood Therapeutics (DWTX) Accounts Payables (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Accounts Payables of $144400.0 for Q1 2026, down 87.48% year-over-year from $1.2 million in Q1 2025, and down 81.02% quarter-over-quarter from $760945.0 in Q4 2025.
Dogwood Therapeutics (DWTX) Accounts Payables (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Accounts Payables for 7 consecutive years, with $144400.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 87.48% year-over-year to $144400.0; the TTM figure through Mar 2026 stood at $144400.0 (down 87.48% YoY), while the FY2025 annual figure was $760945.0, down 38.23% from the prior year.
- Accounts Payables fell to $144400.0 in Q1 2026 per DWTX's latest filing, from $760945.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $1.2 million in Q4 2024 and bottomed at $111913.0 in Q4 2023.
- Historically, Accounts Payables has averaged $479910.8 across 5 years, with a median of $454962.0 in 2024.
- Annual changes were most pronounced in 2024 — Accounts Payables jumped 1000.68% — and 2026, when it sank 87.48%.
- Dogwood Therapeutics' Accounts Payables stood at $573164.0 in 2022, then slumped by 80.47% to $111913.0 in 2023, then surged by 1000.68% to $1.2 million in 2024, then slumped by 38.23% to $760945.0 in 2025, then tumbled by 81.02% to $144400.0 in 2026.
- Business Quant data shows DWTX's Accounts Payables at $144400.0 in Q1 2026, $760945.0 in Q4 2025, and $584602.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - | 411,516.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 144,400.00 |
| Dec 31, 2025 | 760,945.00 |
| Sep 30, 2025 | 584,602.00 |
| Jun 30, 2025 | 498,118.00 |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 1.23 Mn |
| Sep 30, 2024 | 454,962.00 |
| Jun 30, 2024 | 217,762.00 |
| Mar 31, 2024 | 196,759.00 |
| Dec 31, 2023 | 111,913.00 |
| Sep 30, 2023 | 205,369.00 |
| Jun 30, 2023 | 214,305.00 |
| Mar 31, 2023 | 135,094.00 |
| Dec 31, 2022 | 573,164.00 |
| Sep 30, 2022 | 679,416.00 |
| Jun 30, 2022 | 665,538.00 |
| Mar 31, 2022 | 330,690.00 |
| Dec 31, 2021 | 353,863.00 |
| Sep 30, 2021 | 483,496.00 |
| Jun 30, 2021 | 262,590.00 |